Welcome to LookChem.com Sign In|Join Free

CAS

  • or

599191-73-8

Post Buying Request

599191-73-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

599191-73-8 Usage

General Description

4-Iodo-1H-indazol-3-ylamine is a chemical compound with the molecular formula C7H6IN3. It is a derivative of indazole and contains an amino group. This chemical is commonly used in pharmaceutical research as a building block for the synthesis of various biologically active compounds. The presence of the iodo group makes it a useful starting material for the preparation of iodinated indazole derivatives, which can have potential applications in drug discovery and development. It is important to handle and use this compound with care, as it can be hazardous if not properly handled and stored.

Check Digit Verification of cas no

The CAS Registry Mumber 599191-73-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,9,9,1,9 and 1 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 599191-73:
(8*5)+(7*9)+(6*9)+(5*1)+(4*9)+(3*1)+(2*7)+(1*3)=218
218 % 10 = 8
So 599191-73-8 is a valid CAS Registry Number.
InChI:InChI=1/C7H6IN3/c8-4-2-1-3-5-6(4)7(9)11-10-5/h1-3H,(H3,9,10,11)

599191-73-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-Iodo-1H-indazol-3-amine

1.2 Other means of identification

Product number -
Other names 4-iodo-1H-indazol-3-amine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:599191-73-8 SDS

599191-73-8Upstream product

599191-73-8Relevant articles and documents

A Facile and Effcient Synthesis of Some New Indazole Schiff Bases through Conventional and Microwave Irradiation Conditions

Liu, Xing-Hai,Min, Li-Jing,Shi, Hai-Bo,Wu, Hong-Ke,Zhang, Pei-Pei

, p. 15 - 19 (2021/08/12)

A series of new indazole Schiff bases was synthesized under conventional and microwave irradiation conditions by the reactions of 4-iodo-1H-indazol-3-amine with various substituted aldehydes. Their chemical structures were characterized by proton nuclear

NOVEL INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER CONTAINING THE SAME

-

Paragraph 0222-0223, (2020/12/25)

Disclosed are a compound selected from novel indazole derivatives, pharmaceutically acceptable salts thereof, hydrates thereof and stereoisomers thereof, a method for preparing the compound, and a pharmaceutical composition for preventing, alleviating or treating cancer containing the compound as an active ingredient. The novel indazole derivatives exhibit excellent ABL/DDR1 inhibitory efficacy and anti-proliferative efficacy against cancer cells, specifically blood cancer cells, and inhibitory activity against ABL T315I point mutations, thus being useful for the prevention, alleviation or treatment of cancer, specifically blood cancer, especially chronic myelogenous leukemia.

Discovery of novel anti-angiogenesis agents. Part 11: Development of PROTACs based on active molecules with potency of promoting vascular normalization

Shan, Yuanyuan,Si, Ru,Wang, Jin,Zhang, Qingqing,Li, Jing,Ma, Yuexiang,Zhang, Jie

, (2020/08/05)

Our recent investigation is focused on the discovery of anti-angiogenesis agents. Vascular normalization induced by anti-angiogenic agent appears to be a promising strategy. We have developed novel angiogenesis inhibitors with potency of promoting vascular normalization. Herein, we reported the design, synthesis and preliminary evaluation of proteolysis-targeting chimera (PROTACs) based on the previously developed anti-angiogenesis agents. Two PROTACs exhibited potent VEGFR-2 inhibition and anti-proliferative activity against HUVECs. Moreover, they were capable of reducing protein levels of VEGFR-2 in EA.hy926 cells without significant cytotoxicity against HEK293 cells. The novel PROTACs could be used to normalize the abnormal vessels, resulting in efficient delivery of drugs.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 599191-73-8